Oculis Eyes Double DIAMOND After Initial Phase III Success In DME
Plans For Ex-US Partnerships
The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.
